The FDA has approved nivolumab with ipilimumab in certain patients with advanced colorectal cancer. The U.S. Food and Drug Administration (FDA) has approved nivolumab (Opdivo) with ipilimumab (Yervoy) for the treatment of patients 12...
The FDA has approved the Immunotherapy durvalumab in combination with chemotherapy for certain patients with resectable bladder cancer. The U.S. Food and Drug Administration (FDA) has approved durvalumab (Imfinzi) in combination with chemotherapy before...
The FDA has approved the radiotherapy lutetium Lu 177 vipivotide tetraxetan for certain patients with metastatic prostate cancer. The U.S. Food and Drug Administration (FDA) has approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) for...
The FDA has approved the multi-kinase inhibitor cabozantinib for certain adult and pediatric patients with rare neuroendocrine tumors. The U.S. Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx) for patients 12 years and...
The FDA has approved a PD-1 blockade treatment regimen for certain patients with advanced stomach and gastroesophageal cancer. The U.S. Food and Drug Administration (FDA) has granted traditional approval to pembrolizumab (Keytruda) in combination...
The FDA has approved a new combination regimen for certain patients with esophageal cell squamous cell carcinoma. The U.S. Food and Drug Administration (FDA) has approved tislelizumab-jsgr (Tevimbra) in combination with chemotherapy for the...
The FDA has approved a CSF1 small molecule inhibitor for certain patients with symptomatic tenosynovial giant cell tumor. The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza) for the treatment of adult...
The FDA has approved the antibody-drug conjugate brentuximab vedotin, plus lenalidomide and rituximab, for certain cases of pretreated large B-cell lymphoma. The U.S. Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris), in...
The FDA has approved a new MEK inhibitor for certain patients with symptomatic neurofibromatosis type 1. The U.S. Food and Drug Administration (FDA) has approved mirdametinib (Gomekli) for the treatment of patients with neurofibromatosis...
The FDA has approved fam-trastuzumab deruxtecan-nxki for certain HER2-low or HER2-ultralow breast cancers. The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the treatment of unresectable or metastatic, hormone...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More